Home › Amyloidosis › Tennessee
Amyloidosis clinical trials in Tennessee
7 studies for Amyloidosis are looking for participants at sites in Tennessee.
Cities in Tennessee
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- Research Site, Germantown
- Research Site, Nashville
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 23, 2026 · NCT06465810TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- Clinical Trial Site, Nashville
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 15, 2026 · NCT07223203DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
- Clinical Trial Site, Memphis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07358078Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
- Vanderbilt Ingram Cancer Center, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT05145816A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
- University of Tennessee Graduate School of Medicine, Knoxville
RecruitingPhase 1Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT05951816A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
- Research Site, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT07081646A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
- Vanderbilt University Medical Center. /ID# 273510, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 13, 2026 · NCT06158854From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.